BI-765063

N/A

Report date: 2026/03/23 20:03:44
First In Class

Base Information

Drug NameBI-765063
Drug Alias NameOSE-172BI-765063Effi-DEM
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionSignal-regulatory protein alpha inhibitors
TargetsSignal-regulatory protein alpha
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesPoland +[12] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesEffimune
China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. KgOse Immunotherapeutics
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of Head and Neck +[5] 
Inactive IndicationsColorectal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A